Another major step towards the end of the COVID-19 pandemic has been taken this week. The pharmaceutical company Johnson & Johnson has revealed some major news on the success of their new COVID vaccine. Johnson & Johnsonannounced that their single dose vaccine clears the thresholdthat was put ...
Covid-19 and hospitalization with Covid-19(i.e.,Covid-19 diagnosed at or after admission).We compared cohorts defined according to vaccine product received,age,and month of full vaccination with age-specific unvaccinated cohorts by linking statewide testing,hospital,and vaccine registry databases....
As the COVID virus continues toevolve, so does our vaccine response. FromDecember 11, Australians will have access tonew vaccinesthat offer better protection. These "monovalent" booster vaccines are expected to be a better match for currently circulating strains of SARS-CoV-2, the virus that ca...
the primary end point was the efficacy rate of the vaccine in preventingsymptomaticCOVID-19 (including mild, moderate and severe disease) with the onset at least seven days after the second dose. The secondary end point on this trial was the efficacy rate against severe COVID-19. ...
Medical News & Perspectives COVID-19 and mRNA Vaccines—First Large Test for a New Approach Jennifer Abbasi JAMA In August, the government of India granted Emergency Use Authorization to a COVID-19 DNA vaccine. Pharmaceutical firm Zydus Cadila, in partnership with India’s Department of Biotechnol...
pharmaceutical giant Moderna said its COVID-19 vaccine protects against two new variants of the coronavirus. The company said the vaccine triggered an immune response to "all key emerging variants," including those first identified in the UK and South Africa. The researchers looked...
A COVID-19 vaccine designed to be inexpensive and easy to mass produce globally has received emergency use authorization from India’s government,
[00:00.04]The latest COVID-19 vaccine [00:03.72]is set for release in September. [00:07.44]But health experts say it remains unclear [00:12.24]how many Americans will choose to get the new shot. [00:17.68]The efforts...
There have been a number of COVID-19 vaccines in development in the United States and around the world, and one of them has shown some very positive preliminary results in its Phase 3 trial. One particular vaccine developed by Pfizer and German firm BioNTech appears to be more than 90 perc...
"The question about whether there's going to be another variant that is even more transmissible and more infectious than Omicron, we don't know yet," Dr. Katrina Pollock, who leads the COVID-19 vaccine project at the ICL, told Xinhua in an online interview on Thursday. ...